Last updated: April 25, 2026
Who Supplies Daptomycin for Pharmaceutical Manufacturing?
Daptomycin is supplied via a mix of active pharmaceutical ingredient (API) producers, contract manufacturers for drug product, and specialty intermediates. The workable view for procurement and development is to map (1) API sourcing (daptomycin substance) and (2) finished-dose supply chain (drug product and packaging), then cross-check each supplier against regulatory and commercial visibility through inspections, approvals, and published registrations.
What are the major daptomycin API supply sources?
Below are the primary, repeatedly cited daptomycin substance suppliers that show up across commercial and regulatory documentation in the US and Europe.
Key daptomycin API manufacturers (substance suppliers)
| Supplier |
Typical role in the chain |
Evidence of market/regulatory presence |
| Merck KGaA / Merck & Co. supply chain (brand and legacy developer) |
Primary commercial source for US/EU supply historically tied to originator control |
Originator-linked supply and regulatory history for daptomycin products (Cubicin and related filings) [1] |
| Teva |
API or drug product supply participation for generic daptomycin |
US generic portfolio activity for daptomycin implies API and/or finished-dose contracting by Teva or its network [2] |
| Pfizer (Hospira legacy footprint) |
Injection supply chain participant historically for parenterals; often connected to contract manufacturing for generics and authorized equivalents |
Active presence in injectable antibiotic supply networks and parenteral manufacturing footprints used for complex injectables in the US [3] |
| Sandoz / Novartis network |
Generic daptomycin supply participation through authorized/contract manufacturing |
Generic entry and supply chain visibility for parenteral anti-infectives [4] |
| Accord / Hikma / Mylan (Viagra-like but for injectables: parenteral generic network) |
Finished-dose supply participation for generic daptomycin |
US generic market presence for sterile injectables supports a manufacturing-and-distribution model with contract manufacturing [5] |
Procurement implication: For daptomycin, buyers generally do not source a single “one-size” API lane. They qualify multiple routes for (a) daptomycin bulk, (b) sterile compounding or vial-filling, and (c) cold chain and distribution packaging specific to lyophilized vials.
Which finished-dose supply channels matter for procurement?
Daptomycin is marketed as sterile injection (commonly lyophilized powder with reconstitution). That means the drug-product supply chain is dominated by sterile manufacturing capability: vial filling, lyophilization, aseptic processing, labeling, and packaging under GMP.
Drug product suppliers (finished-dose / vial supply)
In practice, drug product suppliers for daptomycin are usually one of these models:
- Originator-branded manufacturing under the originator umbrella for Cubicin and supply allocations.
- Generic manufacturers selling daptomycin for injection under ANDA approvals in the US.
- Contract sterilization and packaging houses producing sterile injectables for multiple brands under QMS-controlled arrangements.
Regulatory listing and distribution visibility for daptomycin drug product is captured through generic approval and commercial availability patterns in the US ANDA market [2,5].
What supplier identities show up via ANDA approvals and labeling?
The US ANDA system connects manufacturers to specific drug product applicants, strength(s), dosage form, and labeling. In daptomycin, ANDA applicants and their manufacturing partners represent the most defensible “supplier” list for finished-dose procurement.
ANDA-linked manufacturer visibility
A typical sourcing list for procurement should include:
- ANDA applicant (the legal manufacturer of record for product labeling)
- Listed manufacturing sites (sterile drug product manufacturing)
- API supplier chain (often not fully disclosed in public ANDA summaries, but can be inferred through inspections, DS filings, and supplier change histories)
Public ANDA and product availability patterns for daptomycin show repeated generic entries from multiple applicants and branded distribution mechanisms tied to parenteral supply chains [2,5].
How to structure an actionable supplier qualification list (API + sterile drug product)
Given daptomycin’s sterile injection format, qualification should be split into two supplier categories.
Category A: Daptomycin API suppliers
Screen and qualify:
- API manufacturing site(s) capable of producing daptomycin substance under GMP
- Change control maturity for polymorph, impurity profile, and residual solvents where relevant
- Supply continuity for batch release and revalidation cadence
Category B: Sterile drug-product manufacturers
Screen and qualify:
- Aseptic processing and/or lyophilization lines with validated sterility assurance
- Vial filling, stoppering, lyophilization, and packaging under controlled conditions
- Labeling and distribution readiness for the specific strength and presentation
What do major regulatory records imply about supplier behavior?
Daptomycin supply in the US and EU has historically followed parenteral antibiotic manufacturing constraints: sterilization capacity, lyophilization throughput, and packaging lines. FDA and EMA regulatory structures emphasize cGMP compliance and inspection outcomes, which effectively limit supplier count to those with validated sterile injectable capability [1,6].
What are the practical procurement supplier “shortlists” used by buyers?
For institutional buyers and manufacturers, the supplier shortlist for daptomycin typically includes:
- Originator supply channel for continuity when generics are constrained
- At least 2 ANDA manufacturers with overlapping distribution regions and different manufacturing sites
- A contract sterile packaging/lyophilization partner where risk is managed through multiple sites
This approach mirrors how injectable anti-infectives are sourced in the generic market through multiple applicants and manufacturing networks [2,5].
Key Takeaways
- Daptomycin supply is best managed as a two-layer chain: daptomycin API substance sourcing plus sterile lyophilized drug product manufacturing and packaging.
- The most defensible supplier identification method is to anchor on originator supply for Cubicin and on ANDA-linked applicants for generic daptomycin drug product availability in the US [2,5].
- Supplier qualification must prioritize sterile injectable and lyophilization capability, not only API access, because bottlenecks often sit in drug product manufacturing capacity [6].
FAQs
1) Who is the originator-linked daptomycin supply source?
The originator-linked supply channel is tied to the legacy developer and commercial supply chain for Cubicin, associated with Merck. [1]
2) Are generic daptomycin suppliers typically API producers or drug-product manufacturers?
Generic daptomycin availability is usually driven by drug-product manufacturers (sterile injection/vial filling/lyophilization) under ANDAs, with API supply coming from a qualifying API upstream network. [2,5]
3) What manufacturing capability is most critical for daptomycin supply continuity?
For daptomycin injection, sterile manufacturing and lyophilization plus packaging capacity are the critical bottlenecks that determine supply stability. [6]
4) How do I identify suppliers that can reliably ship sterile injectable product?
Use ANDA applicant and listed manufacturing site visibility to confirm sterile manufacturing lines tied to daptomycin drug product. [2]
5) What is the most practical supplier risk strategy for daptomycin?
Qualify multiple suppliers across originator plus at least two ANDA drug-product sources and ensure each is tied to different sterile manufacturing sites. [5,6]
References
[1] Merck. (n.d.). Cubicin (daptomycin) prescribing information. Merck & Co. https://www.merck.com/
[2] FDA. (n.d.). Drug approvals and databases (ANDA-related records for daptomycin drug products). U.S. Food and Drug Administration. https://www.fda.gov/
[3] Pfizer. (n.d.). Sterile injectable manufacturing and production footprint information. Pfizer Corporate. https://www.pfizer.com/
[4] Sandoz. (n.d.). Generic sterile injectable portfolio information. Sandoz. https://www.sandoz.com/
[5] Drugs@FDA. (n.d.). Daptomycin approvals and related labeling. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
[6] European Medicines Agency. (n.d.). GMP and inspection framework. EMA. https://www.ema.europa.eu/
